NYSE:HAE Haemonetics (HAE) Stock Price, News & Analysis $73.24 -1.34 (-1.80%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$72.72▼$74.8050-Day Range$73.20▼$91.6452-Week Range$70.74▼$97.97Volume763,164 shsAverage Volume531,885 shsMarket Capitalization$3.73 billionP/E Ratio31.98Dividend YieldN/APrice Target$107.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Haemonetics alerts: Email Address Haemonetics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside46.8% Upside$107.50 Price TargetShort InterestBearish9.99% of Float Sold ShortDividend StrengthN/ASustainability-0.54Upright™ Environmental ScoreNews Sentiment0.74Based on 8 Articles This WeekInsider TradingSelling Shares$585,279 Sold Last QuarterProj. Earnings Growth12.88%From $4.58 to $5.17 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.56 out of 5 starsMedical Sector82nd out of 910 stocksSurgical & Medical Instruments Industry10th out of 95 stocks 3.4 Analyst's Opinion Consensus RatingHaemonetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageHaemonetics has only been the subject of 4 research reports in the past 90 days.Read more about Haemonetics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.99% of the float of Haemonetics has been sold short.Short Interest Ratio / Days to CoverHaemonetics has a short interest ratio ("days to cover") of 7.7.Change versus previous monthShort interest in Haemonetics has recently increased by 5.21%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldHaemonetics does not currently pay a dividend.Dividend GrowthHaemonetics does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreHaemonetics has received a 64.94% net impact score from Upright. Haemonetics seems to create the most significant positive value in categories "Taxes", "Physical diseases", and "Relationships". The positive contribution in the "Physical diseases" impact category is mostly driven by its "Computerized clinical decision support software", "Hemofilters", and "Medical technology engineering" products. See details.Environmental SustainabilityThe Environmental Impact score for Haemonetics is -0.54. Previous Next 3.2 News and Social Media Coverage News SentimentHaemonetics has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Haemonetics this week, compared to 6 articles on an average week.Search Interest2 people have searched for HAE on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Haemonetics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Haemonetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $585,279.00 in company stock.Percentage Held by InsidersOnly 1.80% of the stock of Haemonetics is held by insiders.Percentage Held by Institutions99.67% of the stock of Haemonetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Haemonetics' insider trading history. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Haemonetics are expected to grow by 12.88% in the coming year, from $4.58 to $5.17 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Haemonetics is 31.98, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 128.02.Price to Earnings Ratio vs. SectorThe P/E ratio of Haemonetics is 31.98, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 115.16.Price to Earnings Growth RatioHaemonetics has a PEG Ratio of 1.38. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioHaemonetics has a P/B Ratio of 4.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Haemonetics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Timothy SykesTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…Click here to see a unique election-year trade About Haemonetics Stock (NYSE:HAE)Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.Read More HAE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HAE Stock News HeadlinesSeptember 3, 2024 | americanbankingnews.comShort Interest in Haemonetics Co. (NYSE:HAE) Increases By 5.2%September 3, 2024 | americanbankingnews.comHaemonetics Co. to Post Q3 2025 Earnings of $1.22 Per Share, Zacks Research Forecasts (NYSE:HAE)September 7, 2024 | Paradigm Press (Ad)Kamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… August 28, 2024 | americanbankingnews.comHaemonetics (NYSE:HAE) PT Lowered to $85.00August 28, 2024 | americanbankingnews.comHaemonetics (NYSE:HAE) PT Lowered to $85.00 at CitigroupAugust 24, 2024 | benzinga.comAnalyst Expectations For Haemonetics's FutureAugust 24, 2024 | msn.comImplied Volatility Surging for Haemonetics (HAE) Stock OptionsAugust 22, 2024 | uk.finance.yahoo.comHaemonetics Corp (HAZ.DU)September 7, 2024 | Paradigm Press (Ad)Kamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… August 16, 2024 | finance.yahoo.comHaemonetics’ Vascade MVP XL vascular closure system enters US marketAugust 15, 2024 | forbes.comRethinking Blood Transfusions: Three Changes Will Reduce Transfusions And Improve OutcomesAugust 15, 2024 | prnewswire.comHaemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure SystemAugust 10, 2024 | finance.yahoo.comHaemonetics First Quarter 2025 Earnings: EPS Beats ExpectationsAugust 8, 2024 | markets.businessinsider.comHaemonetics Q1 Profit Slips, Despite Revenue Growth, Reaffirms FY25 Adj. EPS, Revenue RangeAugust 8, 2024 | prnewswire.comHaemonetics 1st Quarter Fiscal Year 2025 Earnings Release Available on Investor Relations WebsiteAugust 7, 2024 | markets.businessinsider.comHaemonetics earnings: here's what to expectAugust 7, 2024 | msn.comHaemonetics Q1 2025 Earnings PreviewJuly 30, 2024 | prnewswire.comHaemonetics Announces CE Mark Certification for the SavvyWire® Pre-Shaped Pressure GuidewireSee More Headlines Receive HAE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Haemonetics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/07/2024Next Earnings (Estimated)11/07/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Supplies Current SymbolNYSE:HAE CUSIP40502410 CIK313143 Webwww.haemonetics.com Phone(781) 848-7100Fax781-848-5106Employees3,657Year Founded1971Price Target and Rating Average Stock Price Target$107.50 High Stock Price Target$125.00 Low Stock Price Target$85.00 Potential Upside/Downside+46.8%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$2.29 Trailing P/E Ratio31.98 Forward P/E Ratio15.99 P/E Growth1.38Net Income$117.56 million Net Margins8.61% Pretax Margin11.02% Return on Equity21.86% Return on Assets9.04% Debt Debt-to-Equity Ratio1.35 Current Ratio3.76 Quick Ratio2.33 Sales & Book Value Annual Sales$1.33 billion Price / Sales2.80 Cash Flow$5.86 per share Price / Cash Flow12.49 Book Value$17.69 per share Price / Book4.14Miscellaneous Outstanding Shares50,953,000Free Float50,036,000Market Cap$3.73 billion OptionableOptionable Beta0.30 Social Links 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Christopher A. Simon (Age 60)CEO, President & Director Comp: $3.26MMs. Anila Lingamneni (Age 56)Executive VP & CTO Comp: $1.09MMs. Michelle L. Basil (Age 52)Executive VP, General Counsel & Secretary Comp: $1.26MMr. Josep Lluis Llorens (Age 62)Executive Vice President of Global Manufacturing & Supply Chain Comp: $1.11MMs. Olga GuyetteSenior Director of Investor RelationsMr. Rajeev VarmaSenior Vice President of Strategy & Corporate DevelopmentMs. Laurie A. Miller (Age 51)Senior VP & Chief Human Resources Officer Dr. Jan Hartmann M.D.Senior VP & Chief Medical OfficerMr. Stewart W. Strong (Age 57)President of Global Hospital Comp: $918.03kMs. Kerri DiPietroSenior Vice President of Global Quality AssuranceMore ExecutivesKey CompetitorsMerit Medical SystemsNASDAQ:MMSIDENTSPLY SIRONANASDAQ:XRAYICU MedicalNASDAQ:ICUINeogenNASDAQ:NEOGQuidelOrthoNASDAQ:QDELView All CompetitorsInsiders & InstitutionsTeachers Retirement System of The State of KentuckySold 900 shares on 8/26/2024Ownership: 0.104%Point72 Asset Management L.P.Bought 140,324 shares on 8/19/2024Ownership: 0.430%Creative PlanningBought 4,445 shares on 8/16/2024Ownership: 0.009%Northwestern Mutual Wealth Management Co.Sold 161 shares on 8/16/2024Ownership: 0.001%Quarry LPBought 471 shares on 8/16/2024Ownership: 0.001%View All Insider TransactionsView All Institutional Transactions HAE Stock Analysis - Frequently Asked Questions How have HAE shares performed this year? Haemonetics' stock was trading at $85.51 on January 1st, 2024. Since then, HAE shares have decreased by 14.3% and is now trading at $73.24. View the best growth stocks for 2024 here. How were Haemonetics' earnings last quarter? Haemonetics Co. (NYSE:HAE) announced its quarterly earnings results on Thursday, August, 8th. The medical instruments supplier reported $1.02 earnings per share for the quarter, missing analysts' consensus estimates of $1.03 by $0.01. The business's revenue for the quarter was up 8.0% compared to the same quarter last year. What is Christopher Simon's approval rating as Haemonetics' CEO? 48 employees have rated Haemonetics Chief Executive Officer Christopher Simon on Glassdoor.com. Christopher Simon has an approval rating of 63% among the company's employees. This puts Christopher Simon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. Who are Haemonetics' major shareholders? Top institutional shareholders of Haemonetics include Dimensional Fund Advisors LP (1.92%), Thrivent Financial for Lutherans (1.67%), Boston Trust Walden Corp (1.40%) and Bank of New York Mellon Corp (0.95%). Insiders that own company stock include Christopher Simon, Michelle L Basil, Anila Lingamneni, Josep Llorens, Stewart W Strong, Laurie A Miller and Dan Goldstein. View institutional ownership trends. How do I buy shares of Haemonetics? Shares of HAE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Haemonetics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Haemonetics investors own include NVIDIA (NVDA), Micron Technology (MU), Johnson & Johnson (JNJ), AbbVie (ABBV), Citigroup (C), Align Technology (ALGN) and This page (NYSE:HAE) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Haemonetics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Haemonetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HAE Stock Alerts